Sprint the fourth batch collection! 2 billion injections are sunny, Hengrui 3 over-reviewed

A few days ago, the official website of the State Drug Administration shows that Zhengda Tianqing Pharmaceutical Group's injection with Parexib sodium, Jiangsu Hengrui Pharmaceutical injection with Parexib sodium and Emeishan Tonghui Pharmaceutical injection with Parexib sodium have been approved for supplementary applications.
recent years, china's public medical institutions terminal Parexib injection sales have grown rapidly, reaching nearly 2 billion yuan in 2019 and up nearly 15% year-on-year in the first half of 2020, according to
-meter intranet data.
more than 20 manufacturers that use Parexib sodium for injections, of which Pfizer has the largest market share.
, 13 companies had reviewed it.
January 29, 2021 drug approval documents pending release of information-1 data show that Parrisheb is a selective epoxyase-2 (COX-2) inhibitor, developed by Famasia (now Pfizer), listed in the European Union in 2002 and in China in 2008.
In recent years, China's public medical institutions terminal Parexib injection sales source: China's public medical institutions terminal competition pattern Mienet data show that in recent years, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal Parexib injection sales increased rapidly, in 2018 after exceeding 1 billion yuan, 2019 has been close to the 2 billion yuan mark, the first half of 2020 year-on-year growth of nearly 15%.
more than 20 manufacturers that use Parexib sodium for injections, of which Pfizer has the largest market share.
note that Pfizer's market share has declined in recent years, falling below 50% from its dominant market in 2017 to the first half of 2020, as domestic drug companies have gained strength.
source: MED2.0 China Drug Review Database injection with Parexib sodium is the fourth batch of collection varieties, before that, 13 enterprises have been evaluated, including Qilu Pharmaceuticals, Hunan Colum Pharmaceuticals, Jiangsu Osaikang Pharmaceuticals, Chengdu Yuandong Biopharmaceuticals, Zhejiang Haizheng Pharmaceuticals and other 9 companies were approved with a consistent evaluation of supplementary applications, Hongguan Biopharmaceuticals, Zhejiang Hangkang Pharmaceuticals, Chengdu Baiyu Pharmaceuticals and other 4 are approved to copy 4 categories of the market, as reviewed.
In addition, Yangzijiang Pharmaceutical Group Guangzhou Hairui Pharmaceuticals, Zhejiang Jinhua Kang Enbei Biopharmaceuticals, Hunan Cylon Pharmaceuticals in the review and approval of the consistent evaluation of supplementary applications (in the drug review center);
source: official website of the State Drug Administration, Mi Net database